drugset / Trial / NCT05565794
Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements
Phase 2
Terminated
2 enrolled
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Incyte Biosciences International Sàrl · collab
NaSingle-groupOpen-labelTreatment
Summary
The aim of this phase II study is to determine whether pemigatinib is clinically efficious after curative local therapy such as surgery/ SBRT or ablation in iCCA patients harboring FGFR2 fusion/rearrangement and to assess the safety profile to support the continuation of the concept in a large, randomized trial for further development.
Timeline
- Start
- 2022-11-11
- Primary completion
- 2025-03-27
- Completion
- 2025-03-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pemigatinib | Small molecule | 13.5 mg | Oral |